Gene and cell therapy (GCT) has the potential to transform medicine, providing long term and potentially curative treatment options for a wide range of diseases. GenScript develops GMP platform to provide vectors, including viral vectors and non-viral vectors. Following the new drug development process, plasmid and virus in different quality levels are provided to meet requirements in different stages with rapid turn-around time.
Different quality levels and quantity options available to follow the GCT development process.
One-stop lentivirus solutions, enables smooth transition from preclinical, through clinical to commercialization.